A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

Prior treatment

• Participant has active or prior CNS or meningealinvolvement of MM.
• Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.

Other illness

• Participant has primary amyloidosis, active plasma cellleukemia (≥5% circulating plasma cells), Waldenströmmacroglobulinemia, or POEMS syndrome.
• Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
• Participant is positive for any of the following: a. HIV: Known to be seropositive for HIV (including any history of HIV). b. Chronic or active hepatitis B c. Active hepatitis C: Hepatitis C infection d. Additional local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations.
• Participant has clinically significant cardiovascular disease.

Other

• Additional exclusion for participants who are planned to receive IsaVRd as induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade 1 with pain
• Participant has significant neurological or psychiatriccondition posing risk or impairing evaluation.
• Participant has any other significant medical conditionthat increases unacceptable risk, interferes with therapydelivery, or confounds evaluation.
• Participant has COPD with an FEV1 < 50% of predicted normal.

• Participants must be 18 years or older, at the time ofsigning the ICF.
• Participant must have documented diagnosis of MMaccording to the IMWG diagnostic criteria.
• Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) andabnormal serum immunoglobulin kappa lambda FLC ratio.
  • 4.Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.
• Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator.
• ECOG performance status Grade of 0 to 2.
• Participant must have adequate organ and bone marrow function.